Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced Non-Small-Cell Lung Cancer and Effect on Patients’ Quality of Life and Adverse Reaction Rate

Ma, Zaiqi; Wang, Yun; Sun, Yonghua; Lin, Gaoyang; Zhao, Zhenqing

doi:10.1155/2022/7898737

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as chemotherapy drugs continue to be used, tumors seem to become more and more resistant causing the killing effect of chemotherapy drugs to gradually lose efficacy [ 2 ]. In addition to this difficulty, the serious adverse effects of chemotherapy on patients are also a problem that chemotherapy drugs need to address urgently [ 3 , 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Exploration of the Use of Natural Compounds in Combination with Chemotherapy Drugs for Tumor Treatment

et al. 2023

Molecules

View full text Add to dashboard Cite

Currently, chemotherapy is the main treatment for tumors, but there are still problems such as unsatisfactory chemotherapy results, susceptibility to drug resistance, and serious adverse effects. Natural compounds have numerous pharmacological activities which are important sources of drug discovery for tumor treatment. The combination of chemotherapeutic drugs and natural compounds is gradually becoming an important strategy and development direction for tumor treatment. In this paper, we described the role of natural compounds in combination with chemotherapeutic drugs in synergizing, reducing drug resistance, mitigating adverse effects and related mechanisms, and providing new insights for future oncology research.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploration of the Use of Natural Compounds in Combination with Chemotherapy Drugs for Tumor Treatment

et al. 2023

Molecules

View full text Add to dashboard Cite

show abstract

“…EML4-ALK is an important tumor driver gene that promotes the occurrence and progression of NSCLC, with an incidence of 3–5% ( 3 ). Targeted therapy for advanced ALK-positive NSCLC can effectively prolong the survival time of patients with significant curative effects ( 4 - 8 ). Various ALK tyrosine kinase inhibitors (ALK-TKIs) have been used to treat EML4-ALK-positive NSCLC patients.…”

Section: Introductionmentioning

confidence: 99%

A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer

Wang¹,

Xu²,

Zhang³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) are mainly used in the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC), but a comprehensive clinical evaluation of ALK-TKIs is lacking. Hence, a comparison of ALK-TKIs for first-line treatment of ALK-positive advanced NSCLC is essential to provide rational drug use and a basis for improving national policies and systems. Methods According to the Guideline for the Administration of Clinical Comprehensive Evaluation of Drugs (2021) and the Technical Guideline for the Clinical Comprehensive Evaluation of Antitumor Drugs (2022), a comprehensive clinical evaluation index system of first-line treatment drugs for ALK-positive advanced NSCLC was established by literature review and expert interviews. We conducted a systematic literature review, meta-analysis, and other relevant data analyses, combined with an indicator system, to establish a quantitative and qualitative integration analysis for each indicator and each dimension of crizotinib, ceritinib, alectinib, ensartinib, brigatinib, and lorlatinib. Results The comprehensive clinical evaluation results of all dimensions were as follows: in terms of safety, alectinib had a lower incidence of grade 3 and above adverse reactions; for effectiveness, alectinib, brigatinib, ensartinib, and lorlatinib showed better clinical efficacy, and alectinib and brigatinib have been recommended by several clinical guidelines; in terms of economy, second-generation ALK-TKIs have more cost-utility advantages, and both alectinib and ceritinib have been recommended by the UK and Canadian Health Technology Assessment (HTA) agencies; for suitability, accessibility, and innovation, alectinib has a higher degree of physician recommendations and patient compliance. Except for brigatinib and lorlatinib, all other ALK-TKIs have been admitted to the medical insurance directory; the accessibility of crizotinib, ceritinib, and alectinib is good, meeting the needs of patients. Second- and third-generation ALK-TKIs have higher blood-brain barrier permeability, stronger inhibition ability, and innovation than first-generation ALK-TKIs. Conclusions Compared with other ALK-TKIs, alectinib performs better across six dimensions and has a higher comprehensive clinical value. The results provide better drug choice and rational use for patients with ALK-positive advanced NSCLC.

show abstract

“…It was reported that CRI alone or combination with EGFR-TKI produced effective therapeutic for EGFR-mutant NSCLC patients 15 . CRI combined with gemcitabine and carboplatin could effectively improve quality of life, prolong the long-term survival rate, and present a good effect on advanced NSCLC patients without gene mutation compared with single chemotherapy 16 . We for the first time explored the effect and mechanism of HCPT combined with CRI on EGFR mutated adenocarcinoma cells and large cell lung cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Development of 10-Hydroxycamptothecin-crizotinib conjugate based on the synergistic effect on lung cancer cells

Liu

Guo

et al. 2022

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

The effect of the combination of 10-Hydroxycamptothecin (HCPT) and crizotinib (CRI) on EGFR- and KRAS-mutant lung cancer cells was investigated and the conjugates of the two drugs were synthesised. HCPT combined with CRI synergistically inhibited the cell growth and proliferation of H1975, HCC827, and H460 without aggravating adverse effect on the normal cells. The combination synergistically enhanced the cell apoptosis rate through releasing Cyto-C by activation of Bcl-2 family-mediated mitochondrial signalling, which was associate with inactivating of EGFR related downstream signalling pathways including AKT, ERK, JNK, and p38 MAPK. Based on this synergy, the conjugates of HCPT and CRI (compounds CH-1 and CH-2 ) with different chemical bonds were synthesised. Compound CH-1 exhibited stronger cytotoxicity than HCPT and CRI alone or in combination. The combination of HCPT and CRI might be a promising therapeutic regimen and the conjugate CH-1 was a potential target drug for the treatment of lung cancer.

show abstract

Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced Non-Small-Cell Lung Cancer and Effect on Patients’ Quality of Life and Adverse Reaction Rate

Cited by 4 publications

References 18 publications

Exploration of the Use of Natural Compounds in Combination with Chemotherapy Drugs for Tumor Treatment

Exploration of the Use of Natural Compounds in Combination with Chemotherapy Drugs for Tumor Treatment

A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer

Development of 10-Hydroxycamptothecin-crizotinib conjugate based on the synergistic effect on lung cancer cells

Contact Info

Product

Resources

About